[{"id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/","commit":"ad64caf371","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a fifth batch of approved products","file":"src/data/spikes/neuroendocrine.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Somatostatin%20analogues\" }]"}]},{"id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/","commit":"06899fbdf4","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: hepatocellular carcinoma, biliary tract cancer, neuroendocrine tumours (deep, with structured outcomes, dosing, toxicity, regulatory","file":"src/data/spikes/neuroendocrine.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"mechanismSteps"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"targets"},{"field":"companies"},{"field":"cancers"},{"field":"trials"},{"field":"terms"}]}]